Castle Biosciences (CSTL) Stock Could Be Undervalued Following Raised 2026 Guidance
Castle Biosciences (CSTL) Lifts Guidance Following Revenue Growth But Is The Valuation Already Priced In
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade
Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $41
Castle Biosciences Stock Gets A Lift From Raised 2026 Outlook
Castle Biosciences Inc (CSTL) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...
Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $40
What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call
Castle Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation
Castle Biosciences (NASDAQ:CSTL) Tops Q3 Estimates and Raises 2026 Revenue Guidance on TissueCypher Momentum
Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript
Castle Biosciences Reports Third Quarter 2026 Results
Castle Biosciences Q3 2026 Earnings Call Transcript
Castle Biosciences Raises FY2026 Sales Guidance from $365.000M-$375.000M to $385.000M-$395.000M vs $373.753M Est
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.